118 related articles for article (PubMed ID: 16085560)
1. Secondary hematological malignancies after breast cancer chemotherapy.
Park MJ; Park YH; Ahn HJ; Choi W; Paik KH; Kim JM; Chang YH; Ryoo BY; Yang SH
Leuk Lymphoma; 2005 Aug; 46(8):1183-8. PubMed ID: 16085560
[TBL] [Abstract][Full Text] [Related]
2. Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: A nationwide population-based cohort.
Jabagi MJ; Vey N; Goncalves A; Le Tri T; Zureik M; Dray-Spira R
Int J Cancer; 2021 Jan; 148(2):375-384. PubMed ID: 32683691
[TBL] [Abstract][Full Text] [Related]
3. Secondary hematological malignancies after treatment of non-metastatic breast cancer.
Arslan C; Ozdemir E; Dogan E; Ozisik Y; Altundag K
J BUON; 2011; 16(4):744-50. PubMed ID: 22331732
[TBL] [Abstract][Full Text] [Related]
4. Hematologic Malignancies Discovered on Investigation of Breast Abnormalities.
Alsadi A; Lin D; Alnajar H; Brickman A; Martyn C; Gattuso P
South Med J; 2017 Oct; 110(10):614-620. PubMed ID: 28973700
[TBL] [Abstract][Full Text] [Related]
5. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience.
Tallman MS; Gray R; Bennett JM; Variakojis D; Robert N; Wood WC; Rowe JM; Wiernik PH
J Clin Oncol; 1995 Jul; 13(7):1557-63. PubMed ID: 7602344
[TBL] [Abstract][Full Text] [Related]
6. How breast cancer chemotherapy increases the risk of leukemia: Thoughts about a case of diffuse large B-cell lymphoma and leukemia after breast cancer chemotherapy.
Zhang B; Zhang X; Li M; Kong L; Deng X; Yu J
Cancer Biol Ther; 2016; 17(2):125-8. PubMed ID: 26861804
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience.
Smith RE; Bryant J; DeCillis A; Anderson S;
J Clin Oncol; 2003 Apr; 21(7):1195-204. PubMed ID: 12663705
[TBL] [Abstract][Full Text] [Related]
8. t(8;16) AML developed subsequent to breast cancer therapy.
Sahin FI; Yilmaz Z; Karakuş S; Boğa S; Akçali Z; DemIrhan B
Hematology; 2006 Jun; 11(3):153-5. PubMed ID: 17326321
[TBL] [Abstract][Full Text] [Related]
9. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
Praga C; Bergh J; Bliss J; Bonneterre J; Cesana B; Coombes RC; Fargeot P; Folin A; Fumoleau P; Giuliani R; Kerbrat P; Hery M; Nilsson J; Onida F; Piccart M; Shepherd L; Therasse P; Wils J; Rogers D
J Clin Oncol; 2005 Jun; 23(18):4179-91. PubMed ID: 15961765
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia after breast cancer: a population-based comparison with hematological malignancies and other cancers.
Beadle G; Baade P; Fritschi L
Ann Oncol; 2009 Jan; 20(1):103-9. PubMed ID: 18647961
[TBL] [Abstract][Full Text] [Related]
11. Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies.
Guillem VM; Collado M; Terol MJ; Calasanz MJ; Esteve J; Gonzalez M; Sanzo C; Nomdedeu J; Bolufer P; Lluch A; Tormo M
Leukemia; 2007 Jul; 21(7):1413-22. PubMed ID: 17476281
[TBL] [Abstract][Full Text] [Related]
12. Secondary bone marrow malignancies after adjuvant chemotherapy for breast cancer: a report of 2 cases and a review of the literature.
Rossi D; Sarti D; Malerba L; Tommasoni S; Visani G; Martignetti A; Fiorentini G
Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 26979247
[TBL] [Abstract][Full Text] [Related]
13. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
Lenz G; Dreyling M; Schiegnitz E; Haferlach T; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2004 Dec; 22(24):4926-33. PubMed ID: 15611507
[TBL] [Abstract][Full Text] [Related]
14. Leukemia incidence following primary breast carcinoma treatment.
Kaplan HG; Malmgren JA; Atwood M
Cancer; 2004 Oct; 101(7):1529-36. PubMed ID: 15378478
[TBL] [Abstract][Full Text] [Related]
15. [Clinical characteristics and prognosis of 35 patients with therapy-related hematological neoplasms].
Lu QS; Xu N; Zhou X; Cai GX; Li L; Li YL; Lu ZY; Huang JX; Liu QF; Liu XL
Zhonghua Xue Ye Xue Za Zhi; 2016 Mar; 37(3):221-6. PubMed ID: 27033760
[TBL] [Abstract][Full Text] [Related]
16. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.
Radaelli F; Onida F; Rossi FG; Zilioli VR; Colombi M; Usardi P; Calori R; Zanella A
Hematology; 2008 Aug; 13(4):195-202. PubMed ID: 18796244
[TBL] [Abstract][Full Text] [Related]
17. Paucity of hematological neoplasia after treatment of Hodgkin disease: observation after long-term follow-up at Cancer Institute, Chennai, south India.
Sagar TG; Chandra A; Raman SG; Swaminathan R
Pediatr Hematol Oncol; 2002; 19(3):197-203. PubMed ID: 11936733
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
Patt DA; Duan Z; Fang S; Hortobagyi GN; Giordano SH
J Clin Oncol; 2007 Sep; 25(25):3871-6. PubMed ID: 17664457
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
20. Case records of the Massachusetts General Hospital. Case 32-2007. A 62-year-old woman with a second breast cancer.
Winer EP; Harris JR; Smith BL; D'Alessandro HA; Brachtel EF
N Engl J Med; 2007 Oct; 357(16):1640-8. PubMed ID: 17942877
[No Abstract] [Full Text] [Related]
[Next] [New Search]
